FindTrial
Sign In

A multicenter clinical-pathological prognostic study of Angioimmunoblastic T-cell lymphoma

Angioimmunoblastic T-cell lymphoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300067405
Enrollment
Unknown
Registered
2023-01-06
Start date
2019-10-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angioimmunoblastic T-cell lymphoma

Interventions

None listed

Sponsors

Changhai Hospital,Second military medical university
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Diagnostic criteria for inclusion in Angioimmunoblastocytic T cell lymphoma refer to 2017 WHO classification of lymphohematopoietic tumors, and the inclusion criteria are as follows: (1)Period for case collection: from January, 2011 to December, 31, 2015 (five years, the time can be according to the conditions of hospital itself); (2)The case should be with complete clinical data, including treatment and follow-up. (3)The case should be confirmed as agioimmunoblastic T cell lymphoma (AITL) by pathologic and immunohistochemical techniques.

Exclusion criteria

Exclusion criteria: The cases without complete clinical data, including especially treatment and follow-up data.

Design outcomes

Primary

MeasureTime frame
Five years OS;Progression free survival;—

Countries

China

Contacts

Public ContactMiaoxia He

Changhai Hospital

hmm26@163.com86 18317172656

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026